查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014788

嬰兒癲癇治療市場：依治療分類、給藥途徑、通路及適應症類型/發病機制分類－2026-2032年全球市場預測

Infantile Spasms Therapeutics Market by Therapeutic Class, Route Of Administration, Distribution Channel, Indication Type / Etiology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，嬰兒癲癇治療市場價值將達到 4.2878 億美元，到 2026 年將成長至 4.5384 億美元，到 2032 年將達到 6.7912 億美元，年複合成長率為 6.78%。

主要市場統計數據
基準年 2025 4.2878億美元
預計年份：2026年 4.5384億美元
預測年份 2032 6.7912億美元
複合年成長率 (%) 6.78%

對臨床情況進行了簡潔扼要的概述，清楚地闡述了重症監護挑戰、診斷進展以及影響嬰兒癲癇治療的戰略挑戰。

嬰兒癲癇是一種早期癲癇性疾病，其病因複雜，核准的治療方案有限，構成了極其緊迫的臨床挑戰。臨床醫師、保險公司和看護者身處一個至關重要的環境中，快速診斷和有效啟動治療能夠重塑神經發育路徑，從而帶來雖小但意義重大的治療前景。臨床工作的重點在於控制癲癇發作、最大限度地減少治療相關副作用以及保護神經發育潛能，因此，既要高度關注現有的治療方法，也要關注新的干涉措施。

先進的診斷技術、新的治療方法和新的護理服務方式如何重新定義治療模式和相關人員的期望。

嬰兒癲癇的治療格局正在經歷一場變革，這主要得益於精準診斷技術的進步、治療方法的擴展以及醫療服務模式的演變。基因和代謝檢測技術的進步加速了病因分類，使臨床醫生能夠更精準地根據潛在的疾病機制制定干涉措施，從而實現個人化治療方法。因此，臨床路徑正從統一的演算法轉向分層式方法，優先考慮在明確特定遺傳或結構性病因後標靶治療。

研究關稅和貿易政策的變化如何影響兒童神經病學藥物的供應鏈、價格形成動態和患者獲取途徑。

關稅結構的政策變化會對嬰兒癲癇治療的整個供應鏈產生連鎖反應，影響生產決策、籌資策略以及獲得特藥的途徑。提高活性成分和成品藥的進口關稅往往會增加依賴跨境供應鏈的治療藥物的成本，進而影響處方集談判、庫存管理以及特藥的地理分佈。如果進口成本上升，製造商可能會考慮將部分生產過程遷回國內、協商長期供應商合約或重新設計包裝和分銷方式以降低單位物流成本等方案。

將治療領域、分銷管道和給藥途徑與臨床引入模式和准入趨勢聯繫起來的深入細分分析。

了解治療細分有助於明確嬰幼兒癲癇領域的臨床需求和研發資源集中方向。在治療分類框架內，抗癲癇藥物和荷爾蒙療法被區分開來；抗癲癇藥物包括標靶治療，例如Vigabatrin，而荷爾蒙療法包括促腎上腺皮質激素和皮質類固醇。這種分類對於理解臨床應用、安全監測需求和分銷物流的差異至關重要。每個治療細分領域都有其獨特的處方模式和監測要求，這些都會影響臨床醫生培訓、住院治療方案和門診追蹤流程。

美洲、歐洲、中東和非洲以及亞太地區的臨床、監管和商業性趨勢正在影響准入和戰略重點。

在全球範圍內，區域趨勢影響嬰幼兒癲癇治療體系的臨床實踐、監管預期和商業性優先事項。在美洲，集中的學術中心和一體化的醫療保健系統往往推動了先進診斷和專科治療方法的早期應用，而支付方結構和區域處方藥清單則影響著藥物獲取途徑和合約策略。因此，該地區的相關人員可能會優先考慮產生可靠的真實世界證據，並與支付方合作，以確保及時獲得治療並支持報銷決策。

企業策略模式揭示了治療方法開發、夥伴關係和准入計劃如何與臨床差異化和實際交付挑戰相契合

在嬰幼兒癲癇領域，主要企業正致力於一系列策略重點，以全面推進治療方案和患者支持體系的建立。有些公司專注於最佳化製劑配方和改進給藥途徑，以提高耐受性並實現門診管理；而另一些公司則投資於伴隨診斷和基因檢測方面的合作研究，以更清晰地界定患者亞群並支持精準醫療的發展路徑。這些措施表明，這些公司既注重臨床差異化，也重視在臨床環境中的實際應用。

為企業制定一致的商業計劃提供切實可行的策略建議，該計劃整合了診斷、支付方合作、供應彈性和證據生成。

行業領導企業可以透過協調臨床開發、市場准入策略和營運能力，採取果斷措施來改善患者預後和提升商業性績效。首先，企業應將病因診斷策略納入開發項目和商業計劃，確保臨床試驗和真實世界數據（REW）的收集能夠反映嬰兒癲癇患者群體的異質性。這樣做將提高試驗終點的有效性，並有助於就特定適應症的核准和報銷進行討論。此外，投資於劑型創新和看護者為中心的給藥方案，將減少門診管理的障礙，並提高病患的用藥遵從性。

採用穩健透明的調查方法，結合專家訪談、臨床文獻綜述、監管和專利分析以及資料三角驗證，以檢驗研究結果。

本分析的調查方法結合了結構化的原始研究、廣泛的二手資訊整合以及嚴謹的檢驗，以確保研究的可靠性和有效性。原始研究包括對兒童神經科、醫院藥劑師、醫療系統領導者和保險公司代表進行深入訪談，以了解臨床實踐模式、影響藥物選擇決策的因素以及營運限制。這些訪談提供了不同醫療機構的診斷流程、治療啟動決策和後續照護模式的定性見解。

一份簡潔、全面的分析報告，重點闡述了綜合臨床創新、營運實施和實證策略如何改善治療機會和發展結果。

總之，嬰兒癲癇的治療格局正處於一個轉折點，精準診斷、治療創新和不斷發展的護理模式在此交匯融合，為改善臨床療效創造了重要機會。相關人員面臨兩大挑戰：一是證明療效，二是確保治療方法切實有效。這需要協調一致的策略，涵蓋臨床開發、實證醫學、醫保合作和供應鏈設計。透過將臨床終點與神經發育結果結合，並投資於縱向資料收集，申辦者可以提升其在創新治療方法和現有藥物再利用方面的價值提案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療分類分類的嬰兒癲癇治療市場

  • 抗癲癇藥物/抗癲癇藥（AEDs）
    • Vigabatrin
    • 左乙拉西坦
    • 托皮拉馬特
    • 唑尼沙胺
    • 丙戊酸
  • 荷爾蒙療法
    • 促腎上腺皮質激素
    • 皮質類固醇
  • 聯合治療
    • ACTH +Vigabatrin
    • 類固醇+抗癲癇藥物

第9章 嬰兒癲癇治療藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 口服
    • 解決方案
    • 藥片

第10章 嬰兒癲癇治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 嬰兒癲癇治療藥物的市場適應症類型 / 依病因分類

  • 嬰兒特發性發性癲癇
  • 症狀性嬰兒癲癇
  • 嬰兒不明原因癲癇發作

第12章 嬰兒癲癇治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 嬰兒癲癇治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 嬰兒癲癇治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國嬰兒癲癇治療市場

第16章：中國嬰兒驚厥治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amneal Pharmaceuticals LLC
  • BIOSPACE, INC.
  • CIPLA LIMITED
  • Eisai Co., Ltd.Marinus Pharmaceuticals, Inc.
  • Endo International plc
  • Genix Pharma
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Mallinckrodt plc
  • Marinus Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • MSN Laboratories
  • ORPHELIA Pharma
  • Ovid Therapeutics, Inc.
  • Sanofi SA
  • SGPharma Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma SA
  • Zydus Group
Product Code: MRR-43127F727967

The Infantile Spasms Therapeutics Market was valued at USD 428.78 million in 2025 and is projected to grow to USD 453.84 million in 2026, with a CAGR of 6.78%, reaching USD 679.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 428.78 million
Estimated Year [2026] USD 453.84 million
Forecast Year [2032] USD 679.12 million
CAGR (%) 6.78%

A concise clinical landscape overview that articulates the critical care challenges, diagnostic progress, and strategic imperatives shaping infantile spasms therapeutics

Infantile spasms present a uniquely urgent clinical challenge characterized by an early-life seizure disorder with complex etiologies and a constrained set of approved therapeutic options. Clinicians, payers, and caregivers operate within a high-stakes environment where rapid diagnosis and initiation of effective therapy can reshape neurodevelopmental trajectories, making the therapeutic landscape small in scale but large in consequence. The clinical priorities center on seizure control, minimization of treatment-related adverse effects, and preservation of neurodevelopmental potential, which together drive intense focus on both established regimens and emerging interventions.

Across clinical practice, diagnostic advances and heightened awareness among pediatric neurologists and neonatologists have shortened time-to-treatment in many centers, but variability in access persists. This variation stems from differences in referral pathways, inpatient versus outpatient management capacity, and constrained availability of certain specialty therapies in geographically dispersed settings. Consequently, health systems and industry stakeholders alike must reconcile clinical imperatives with operational realities to ensure timely delivery of care.

In parallel, regulatory and reimbursement considerations create both friction and opportunity. The intersection of orphan disease pathways, evolving evidence standards for neurodevelopmental outcomes, and payer scrutiny of high-cost therapies requires sponsors and health system leaders to design evidence packages that demonstrate meaningful clinical benefit beyond seizure control. Therefore, a strategic approach that integrates clinical trial design, real-world evidence generation, and stakeholder engagement is essential to advance interventions that meaningfully improve outcomes for affected infants and their families.

How precision diagnostics, emerging therapeutic modalities, and new care delivery approaches are together redefining treatment paradigms and stakeholder expectations

The infantile spasms treatment landscape is undergoing transformative shifts driven by innovations in precision diagnostics, expanded therapeutic modalities, and evolving care delivery models. Advances in genetic and metabolic testing have accelerated etiologic classification, enabling clinicians to match interventions more closely to underlying disease mechanisms and thereby personalizing treatment choices. As a result, clinical pathways are adapting from one-size-fits-all algorithms toward stratified approaches that prioritize targeted therapies when a specific genetic or structural cause is identified.

Concurrently, therapeutic innovation extends beyond incremental improvements to established regimens. Novel formulations, repurposed compounds, and biologic strategies are entering development pipelines with an emphasis on improved tolerability and sustained developmental outcomes. These scientific advances are reshaping stakeholder expectations and prompting regulators to signal openness to integrated endpoints that combine seizure metrics with developmental assessments.

Care delivery has also shifted, with digital health tools and tele-neurology augmenting referral networks and follow-up care, thus improving access in underserved regions. Payers and providers increasingly seek evidence of longer-term functional benefit, which encourages manufacturers to invest in longitudinal studies and real-world evidence platforms. Taken together, these shifts are converging to create a more nuanced, patient-centered ecosystem that rewards demonstrable impact on both seizures and neurodevelopmental trajectories.

An examination of how changes in import duties and trade policy can alter pharmaceutical supply chains, pricing dynamics, and patient access pathways in pediatric neurology

Policy shifts in tariff structures can ripple across the infantile spasms supply chain with implications for manufacturing decisions, procurement strategies, and access to specialty therapeutics. Increased import duties on active pharmaceutical ingredients or finished drug products tend to raise landed costs for therapies that rely on cross-border supply chains, which can in turn influence formulary negotiations, inventory management practices, and the geographic distribution of specialty products. When import costs rise, manufacturers may evaluate options such as onshoring certain production steps, negotiating long-term supplier contracts, or redesigning packaging and distribution to reduce per-unit logistics expenses.

Moreover, tariffs can interact with regulatory and reimbursement frameworks. Payers responding to cost pressures may tighten coverage criteria, adopt step therapy practices, or insist on more robust health economic evidence to justify access to high-cost treatments. These dynamics can affect the timing of commercial launches and the structure of patient access programs, particularly for therapies administered in hospital settings or those requiring cold-chain logistics. In response, companies often accelerate engagement with payers and health systems to design access pathways that mitigate pricing impacts while maintaining continuity of care for patients.

Lastly, tariffs can prompt greater emphasis on regional manufacturing hubs and strategic inventory positioning. Stakeholders may pursue risk-sharing agreements, localized contract manufacturing partnerships, or strategic stockpiling to preserve supply continuity. By proactively modeling tariff scenarios and aligning supply chain responses with clinical access priorities, manufacturers and health systems can reduce volatility and safeguard treatment availability for infants with spasms.

Insightful segmentation analysis that links therapeutic classes, distribution channels, and routes of administration to clinical adoption patterns and access dynamics

Understanding therapeutic segmentation clarifies where clinical demand and development energy concentrate within the infantile spasms arena. The therapeutic class framework separates anti-epileptic drugs from hormonal therapies, with the anti-epileptic segment exemplified by targeted agents such as vigabatrin, while hormonal approaches encompass adrenocorticotropic hormone and corticosteroids; this classification is critical to appreciating differences in clinical adoption, safety monitoring needs, and distribution logistics. Each therapeutic class carries distinct prescribing patterns and monitoring requirements, which in turn shape clinician training, inpatient care protocols, and outpatient follow-up routines.

Distribution channel segmentation highlights divergent access pathways that matter for operational planning. Hospital pharmacies serve as principal channels for inpatient initiation and monitoring of complex regimens, while retail pharmacies support ongoing outpatient dispensing and community access, and online pharmacies play an increasing role in specialty medication fulfillment and home delivery models. These channels differ in their reimbursement mechanisms, patient counseling capabilities, and ability to support cold-chain or controlled distribution products, so commercial strategies must align channel choice with therapy-specific handling and administration needs.

Route of administration further nuances clinical and commercial approaches, with injectable preparations requiring intramuscular or intravenous administration that often necessitates facility-based care and trained clinicians, whereas oral formulations in solution or tablet form facilitate outpatient initiation and caregiver-managed dosing. The administration route affects adherence considerations, caregiver education requirements, and the design of patient support programs, and it influences how manufacturers prioritize formulation innovation to improve tolerability and ease of use. Recognizing how therapeutic class, distribution channel, and route of administration intersect enables stakeholders to tailor development, market access, and service delivery strategies to the realities of clinical practice.

Regional clinical, regulatory, and commercial dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access and strategic priorities

Regional dynamics shape clinical practice, regulatory expectations, and commercial prioritization across global infantile spasms care delivery systems. In the Americas, concentrated academic centers and integrated health systems often drive early adoption of advanced diagnostics and specialty therapies, while payer structures and regional formularies influence access pathways and contracting strategies. Consequently, stakeholders in this region may prioritize robust real-world evidence generation and payer engagement to secure timely access and to support reimbursement decisions.

Within Europe, Middle East & Africa, heterogeneity across health systems yields variable diagnostic capacity and resource allocation, with some markets demonstrating rapid uptake of genetic testing and biologic therapies, whereas others remain reliant on more traditional inpatient-based treatment models. This variation necessitates differentiated market approaches that incorporate capacity-building initiatives and local clinical education to standardize care where possible. Additionally, regulatory harmonization efforts in Europe and emerging reimbursement frameworks in the Middle East can create opportunities for aligned product launches.

Asia-Pacific presents a diverse landscape where populous markets combine rapidly expanding specialty care infrastructure with variable regulatory pathways and local manufacturing capabilities. In several countries, public health priorities and evolving neonatal care programs have led to improved early detection and referral, while manufacturers may leverage regional production hubs and partnership models to enhance supply chain resilience. Across all regions, tailoring evidence generation, distribution strategies, and stakeholder engagement to regional clinical practices and policy environments remains essential to supporting access and improving outcomes for infants affected by spasms.

Corporate strategy patterns revealing how therapy development, partnerships, and access programs are aligned to clinical differentiation and practical delivery challenges

Leading companies operating in the infantile spasms domain are pursuing an array of strategic priorities that collectively advance therapeutic options and patient support infrastructure. Several firms have concentrated on formulation optimization and route-of-administration improvements to enhance tolerability and enable outpatient management, while others have invested in companion diagnostics and genetic testing collaborations to better define patient subgroups and support precision care pathways. These moves demonstrate a dual focus on clinical differentiation and practical usability in real-world settings.

Partnership and alliance activity is also prominent, with commercial and academic collaborations accelerating translational research and post-approval evidence generation. Firms are increasingly integrating pharmacovigilance and patient support services to strengthen adherence and to monitor long-term developmental outcomes, acknowledging the importance of longitudinal data for clinicians and payers alike. In addition, some companies are exploring manufacturing partnerships and regional supply strategies to improve availability in markets with constrained cold-chain or specialty pharmacy infrastructures.

From a commercial standpoint, organizations are refining access programs, engaging payers early, and designing outcomes-based contracting models to align value with cost. These tactical approaches reflect an understanding that clinical efficacy must be paired with demonstrable functional benefit and feasible delivery models to achieve broader adoption. Overall, corporate strategies in this space balance scientific innovation with pragmatic efforts to ensure therapies reach infants in need.

Practical and strategic recommendations for companies to integrate diagnostics, payer engagement, supply resilience, and evidence generation into cohesive commercial plans

Industry leaders can take decisive steps to improve patient outcomes and commercial performance by aligning clinical development, access strategies, and operational capabilities. First, companies should integrate etiologic diagnostic strategies into development programs and commercial planning so that trials and real-world evidence collection reflect the heterogeneity of the infantile spasms population; doing so enhances the relevance of trial endpoints and supports targeted labeling and reimbursement dialogues. In addition, investing in formulation innovation and caregiver-centric delivery solutions will reduce barriers to outpatient management and improve adherence.

Second, proactive payer engagement and flexible contracting approaches can mitigate access friction. Engaging payers early to agree on meaningful clinical and developmental endpoints, and exploring outcomes-based or risk-sharing agreements, can help companies demonstrate value to health systems while preserving patient access. Concurrently, establishing robust patient support services and education resources will assist families and clinicians in navigating complex treatment pathways and monitoring requirements.

Third, supply chain resilience should be prioritized through strategic manufacturing partnerships, regional inventory strategies, and scenario planning for trade policy impacts. Companies should also build longitudinal evidence platforms and registries to capture developmental outcomes and safety data over time, since these data support adoption, inform guideline updates, and strengthen payer negotiations. By coordinating clinical, commercial, and operational initiatives, industry leaders can deliver measurable improvements in care and create sustainable paths to access for innovative therapies.

A robust and transparent research methodology combining expert interviews, clinical literature review, regulatory and patent analysis, and data triangulation to validate insights

The research methodology underpinning this analysis combined structured primary research with extensive secondary source synthesis and rigorous triangulation to ensure credibility and relevance. Primary research included in-depth interviews with pediatric neurologists, hospital pharmacists, health system leaders, and payer representatives to capture clinical practice patterns, formulary decision drivers, and operational constraints. These engagements provided qualitative insights into diagnostic workflows, treatment initiation decisions, and follow-up care models across diverse care settings.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, clinical trial registries, regulatory approvals, and product labeling to map therapeutic mechanisms, safety profiles, and approved indications. Patent landscapes and public company disclosures were examined to understand development trajectories, manufacturing footprints, and partnership activities. Data from clinical registries and real-world evidence sources were analyzed to contextualize longitudinal outcomes and to identify evidence gaps relevant to payers and guideline committees.

Data synthesis involved triangulating qualitative input and secondary findings to validate emergent themes and to highlight areas of consensus and controversy. Where possible, quantitative datasets were cross-checked against multiple independent sources to ensure consistency. Throughout, methodological safeguards such as interviewer guides, respondent validation, and iterative hypothesis testing were employed to reduce bias and to enhance the reliability of the conclusions presented.

A concise synthesis highlighting how integrated clinical innovation, operational execution, and evidence strategies can improve therapeutic access and developmental outcomes

In summary, the infantile spasms therapeutics landscape stands at an inflection point where precision diagnostics, therapeutic innovation, and evolving care models converge to create meaningful opportunities for improved clinical outcomes. Stakeholders face the twin imperatives of demonstrating functional benefit and ensuring practical delivery of therapies, which requires coordinated strategies spanning clinical development, evidence generation, payer engagement, and supply chain design. By aligning clinical endpoints with neurodevelopmental outcomes and by investing in longitudinal data capture, sponsors can strengthen the value proposition of novel and repurposed therapies alike.

Operationally, differences in regional infrastructure and distribution channel dynamics necessitate tailored approaches that address local diagnostic capacity, inpatient-to-outpatient transition pathways, and logistics. Companies that prioritize formulation improvements, caregiver support, and regional supply resilience will be better positioned to achieve sustained clinical uptake. Ultimately, success will depend on an integrated view that balances scientific innovation with pragmatic execution, thereby creating pathways for timely access to effective therapies and improved life-course outcomes for infants affected by spasms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infantile Spasms Therapeutics Market, by Therapeutic Class

  • 8.1. Antiepileptic / Anticonvulsant Drugs (AEDs)
    • 8.1.1. Vigabatrin
    • 8.1.2. Levetiracetam
    • 8.1.3. Topiramate
    • 8.1.4. Zonisamide
    • 8.1.5. Valproate
  • 8.2. Hormonal Therapies
    • 8.2.1. Adrenocorticotropic Hormone
    • 8.2.2. Corticosteroids
  • 8.3. Combination Therapies
    • 8.3.1. ACTH + Vigabatrin
    • 8.3.2. Steroids + AEDs

9. Infantile Spasms Therapeutics Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Oral
    • 9.2.1. Solution
    • 9.2.2. Tablet

10. Infantile Spasms Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Infantile Spasms Therapeutics Market, by Indication Type / Etiology

  • 11.1. Idiopathic Infantile Spasms
  • 11.2. Symptomatic Infantile Spasms
  • 11.3. Cryptogenic Infantile Spasms

12. Infantile Spasms Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infantile Spasms Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infantile Spasms Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Infantile Spasms Therapeutics Market

16. China Infantile Spasms Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amneal Pharmaceuticals LLC
  • 17.6. BIOSPACE, INC.
  • 17.7. CIPLA LIMITED
  • 17.8. Eisai Co., Ltd.Marinus Pharmaceuticals, Inc.
  • 17.9. Endo International plc
  • 17.10. Genix Pharma
  • 17.11. Hetero Labs Ltd.
  • 17.12. Intas Pharmaceuticals Ltd.
  • 17.13. Ionis Pharmaceuticals, Inc.
  • 17.14. Mallinckrodt plc
  • 17.15. Marinus Pharmaceuticals, Inc.
  • 17.16. Merz Pharma GmbH & Co. KGaA
  • 17.17. MSN Laboratories
  • 17.18. ORPHELIA Pharma
  • 17.19. Ovid Therapeutics, Inc.
  • 17.20. Sanofi S.A.
  • 17.21. SGPharma Pvt. Ltd.
  • 17.22. Teva Pharmaceutical Industries Ltd.
  • 17.23. UCB Pharma SA
  • 17.24. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 178. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 198. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 208. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 218. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
  • TABLE 239. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)